Abstract
Gene amplification and/or overexpression of the c-erbB-2/HER2/neu tyrosine kinase are linked with poor prognosis in breast cancer. This is manifest in shorter disease-free intervals, increased risk of metastasis, and resistance to many types of therapy. The molecular mechanisms and signaling circuitry underlying these phenomena are now being elucidated. c-erbB-2, although having no known soluble ligand, is transactivated by heterodimerization with other family members (EGFR, c-erbB-3, c-erbB-4). Receptor activation potentiates tumor cell motility, protease secretion and invasion, and also modulates cell cycle checkpoint function, DNA repair, and apoptotic responses. Since it is expressed at low levels in normal adult tissues, c-erbB-2 is an ideal target for therapy. There is reason for optimism that agents targeting c-erbB-2 signaling will have profound and selective effects in breast cancer, either as single agents or more likely in combination with other therapeutic agents, to enhance their potency.
Article PDF
Similar content being viewed by others
REFERENCES
D. Harari and Y. Yarden (2000). Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19:6102-6114.
S. Sundaresan, E. Penuel, and M. Sliwkowski (1999). The biology of human epidermal growth factor receptor 2. Curr. Oncol. Rep. 1:16-22.
Y. Yarden and M. X. Sliwkowski (2001). Untangling the erbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-137.
L. N. Klapper, M. H. Kirschbaum, M. Sela, and Y. Yarden (2000). Biochemical and clinical implications of the erbB/HER signalling network of growth factor receptors. Adv. Cancer Res. 77:25-79.
B. P. Nicholson (2000). Ongoing and planned trials of hormonal therapy and trastuzumab. Semin. Oncol. 27:33-37.
D. Yu, J. Hamada, H. Zhand, G. L. Nicolson, and M. C. Hung (1992). Mechanisms of c-erbB-2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 7:2263-2270.
S. A. Eccles (2000). Cell biology of lymphatic metastasis: The potential role of c-erbB oncogene signalling. Recent Results Cancer Res. 157:41-54.
S. Ménard, E. Tagliabue, M. Campiglio, and S. Pupa (2000). Role of HER2 gene overexpression in breast carcinoma. J. Cell Physiol. 182:150-162.
F. Révillion, J. Bonneterre, and J. P. Peyrat (1998). ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer 34:791-808.
A. D. Thor, S. Liu, S. Edgerton, D Moore II, K. M. Kasowitz, C.C. Benz, D.F. Stern, and M.P. DiGiovanna (2000). Activation (tyrosine phosphorylation) of erbB-2 (HER2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 18:3230-3239.
X. Ouyang, T. Gulliford, G. C. Huang, C. Harper-Wynne, S. Shousha, and R. J. Epstein (2001). Multisite phosphotyping of the erbB-2 oncoprotein in human breast cancer. Mol. Diagno. 6:17-25.
C. Sweeney and K. L. Carraway III (2000). Ligand discrimination by ErbB receptors: Differential signalling through differential phosphorylation site usage. Oncogene 19:5568-5573.
F. Gebhardt, K. S. Zanker, and B. Brandt (1998). Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases and bone marrow micrometastases from breast cancer patients Biochem. Biophys. Res. Commun. 247:319-323.
M. A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga (2001). Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:4744-4749.
X. Jing, K. Kakudo, M. Murakami, Y. Nakamura, Y. Yokoi, Q. Yang, S. Oura, and T. Sakurai (1999). Intraductal spread of invasive breast carcinoma has a positive correlation with c-erbB-2 over-expression and vascular invasion. Cancer 86:439-448.
S. Braun, G. Schlimok, I. Heumos, G. Schaller, L. Riethdorf, G. Reithmuller, and K. Pantel (2001). erbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res. 61:1890-1895.
B. Brandt, A. Roetger, S. Heidl, C. Jackisch, R. J. Leffe, G. Assmann, and K. S. Zanker (1998). Isolation of bloodborne epithelium-derived c-erbB-2 protein-positive clustered cells from peripheral blood of breast cancer patients. Int. J. Cancer 76:824-828.
P. Uciechowski, C. Eder, B. Bockmann, B. Suchy, G. Driesel, S. Jackel, I. Kusiak, H.-J. Grill, and M. Geising (2000). Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Br. J. Cancer 83:1664-1673.
B. D'Souza and J. Taylor-Papadimitriou (1994). Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc. Natl. Acad. Sci. U.S.A. 91:7702-7706.
T. Shibata, A. Ochiai, Y. Kanai, S. Akimoto, M. Gotoh, N. Yasui, R. Machinami, and S. Hirohashi (1996). Dominant negative inhibition of the association between β-catenin and c-erbB-2 by N-terminally deleted β catenin suppresses the invasion and metastasis of cancer cells. Oncogene 13:883-889.
M. Tan, R. Grijalva, and D. Yu (1999). Heregulin β-1 activated phosphatidyl-inositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signalregulated kinase. Cancer Res. 59:1620-1625.
B. D'Souza, F. Berdichevsky, N. Kyprianou, and J. Taylor-Papadimitriou (1993). Collagen-induced morphogenesis and expression of the β2 integrin subunit is inhibited in c-erbB-2-transfectedhumanmammaryepithelial cells. Oncogene 8:1797-1806.
M. A. Adelsman, J. B. McCarthy, and Y. Shimizu (1999). Stimulation of β1-intgrin function by epidermal growth factor and heregulin β has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Mol. Biol. Cell 10:2861-2878.
K. M. Ignatoski, T. Maehama, S. M. Markwart, J. E. Dixon, D. L. Livant, and S. P. Ethier (2000). ErbB overexpression confers a PI3 kinase dependent invasion capacity on human mammary epithelial cells. Br. J. Cancer 82:666-674.
D. Gambaletta, A. Marchetti, L. Benedetti, A. M. Mercurio, A. Sacchi, and R. Falconi (2000). Co-operative signalling between α6β4 integrin and erbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion. J. Biol. Chem. 275:10604-10610.
S.-S. Lo, S. H. Lo, S.-C. Wang, and M.-C. Hung (1999). Inhibition of focal contact formation in cells transformed by p185neu. Mol. Carcinog. 25:150-154.
R. Vadlamudi, L. Adam, B. Tseng, L. Costa, and R. Kumar (1999). Transcriptional upregulation of paxillin expression by heregulin in human breast cancer cells. Cancer Res. 59:2843-2846.
Y. Li, F. Hua, K. L. Carraway, and C. A. Carothers Carraway (1999). The p185neu-containing glycoprotein complex of a microfilament-associated signal transduction particle. J. Biol. Chem. 274:25651-25658.
M. Komatsu, S. Jepson, M. E. Arango, C. A. Carothers Caraway, and K. L. Carraway (2001). Muc4/sialomucin complex, an intramembrane modulator of erbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene 20:461-471.
D. Zhu and L. Bourguignon (1996). Overexpression of CD44 in p185 neu-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid mediated membrane cytoskeleton interaction and cell adhesion. Oncogene 12:2309-2314.
F. J. Xu, S. Stack, C. Boyer, K. O'Briant, R. Whitaker, G. B. Mills, Y. H. Yu, and R. C. Bast (1997). Heregulin and agonist anti-p185 (c-erbB-2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185 (c-erbB2): Increased invasiveness may contribute to poor prognosis. Clin. Cancer Res. 3:1629-1634.
A. Roetger, A. Merschjann, T. Dittmar, C. Jackisch, A. Barnekow, and B. Brandt (1998). Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by us of an extravasation model. Am. J. Pathol. 153:1797-1806.
A. F. Chambers, G. N. Naumov, H. J. Varghese, K. V. Nadkarni, I. C. MacDonald, and A. C. Groom (2001). Critical steps in haematogenous metastasis: An overview. Surg. Oncol. Clin. N. Am. 10:243-255.
A. Mazumdar, L. Adam, D. Boyd, and R. Kumar (2001). Heregulin regulation of urokinase plasminogen activator and its receptor: Human breast epithelial cell invasion. Cancer Res. 61:400-405.
D. Giunciuglio, M. Culty, G. Fassina, L. Masiello, A. Melchiori, G. Paglialunga, G. Arand, F. Ciardiello, F. Basolo, E.W. Thompson, and A. Albini (1995). Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int. J. Cancer 63:815-822.
M. Tan, J. Yao, and D. Yu (1997). Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57:1199-1205.
B. H. Brandt, A. Roetger, T. Dittmar, G. Nicolai, M. Seeling, A. Merschjann, J.-R. Nofer, G. Dehmer-Moller, R. Junker, G. Assmann, and K. H. Zaenker (1999). C-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J. 13:1939-1949.
L. Adam, R. Vadlamudi, S. B. Kondapaka, J. Chernoff, J. Mendelsohn, and R. Kumar (1998). Heregulin regulates cytoskeletal reorganisation and cell migration through the p21-activated kinase 1 via phosphatidylinositol-3 kinase. J. Biol. Chem. 273:28238-28246.
A. Grothey, R. Hashizume, H. Ji, B. E. Tubb, C. W. Patrick, D. Yu, E. E. Mooney, and P. D. McCrea (2000). C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 19:4864-4875.
K. S. R. Spencer, D. Graus-Porta, J. Leng, N. E. Hynes, and R. L. Klemke (2000). erbB2 is necessary for induction of carcinoma cell invasion by erbB family receptor tyrosine kinases. J. Cell Biol. 148:285-397.
V. S. Sivaraman, H. Wang, G. J. Nuova, and C. C. Malbon (1997). Hyper-expression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99:1478-1483.
S. Zrihan-Licht, Y. Fu, J. Settleman, K. Schinkmann, L. Shaw, I. Keydar, S. Avraham, and H. Avraham (2000). RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer invasion. Oncogene 19:1318-1328.
A. H. Talukder, L. Adam, A. Raz, and R. Kumar (2000). Heregulin regulation of autocrine motility factor expression in human tumor cells. Cancer Res. 60:474-480.
R. Bagheri-Yarmand, R. K. Vadlamudi, R.-A.Wang, J. Mendelsohn, and R. Kumar (2000). Vascular endothelial growth factor upregulation via p21-activated kinase-1 signalling regulates heregulin-β1-mediated angiogenesis. J. Biol. Chem. 275:39451-39457.
S. Xiong, R. Grijalva, L. Zhang, N. T. Nguyen, P. W. Pisters, R. E. Pollock, and D. Yu (2001). Upregulation of vascular endothelial growth factor in breast cancer cells by the heregulinβ1-activated p38 signalling pathway enhances endothelial cell migration. Cancer Res. 61:1727-1732.
A. Petit, J. Rak, W. C. Hung, P. Rockwell, N. Goldstein, B. Fendly, and R. S. Kerbel (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151:1523-1531.
W. B. Carter and M. D. Ward (2000). HER2 regulatory control of angiopoietin-2 in breast cancer. Surgery 128:153-158.
W. B. Carter, J. B. Hoying, C. Boswell, and S. K. Williams (2001). HER2/NEU overexpression induces endothelial cell retraction. Int. J. Cancer 91:295-299.
R. Mass (2000). The role of HER-2 expression in predicting response to therapy in breast cancer. Semin. Oncol. 27: 46-52.
D. Yu and M.-C. Hung (2000). Role of erbB2 in breast cancer chemosensitivity. Bioessays 22:673-680.
H. B. Burke, A. Hoang, J. D. Iglehart, and J. R. Marks (1998). Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 82:874-877.
S. De Placido, C. Carlomagno, M. De Laurentis, and A. R. Bianco (1998). c-erbB-2 predicts tamoxifen efficacy in breast cancer patients Breast Cancer Res. Treat. 52:55-64.
A. Jukkola, R. Bloigu, E.-R. Savolainen, K. Holli, and G. Blanco (2001). c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur. J. Cancer 37:347-354.
R. Colomer, S. Montero, A. Lluch, B. Ojeda, A. Barnadas, A. Casado, B. Massuti, H. Cortes-Funes, and B. Lloveras (2000). Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin. Cancer. Res. 6:2356-2362.
L. N. Harris, L. Yang, C. Tang, D. Yang, and R. Lupu (2000). Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin β-2. Clin. Cancer Res. 4:1005-1012.
S. Sleijfer, J. G. W. Asschert, H. Timmer-Bosscha, and N. H. Mulder (1998). Enhanced sensitivity to tumor necrosis factor α in doxorubicin resistant tumor cell lines due to down-regulated c-erbB-2 Int. J. Cancer 77:101-106.
D. Yu, T. Jing, B. Liu, M. Tan, T. J. McDonnell, and M.-C. Hung (1998). Overexpression of erbB-2 blocks Taxol-induced apoptosis by upregulation of p21cip1, which inhibits p34cdc2 kinase. Mol. Cell 2:581-591.
M.D. Pegram, R. S. Finn, K. Arzoo, M. Beryt, R. J. Pietras, and D. J. Slamon (1997).The effect of HER2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-557.
M. A. Alaoui-Jamali, J. Paterson, A.-E. Al Moustafa, and L. Yen. (1997). The role of erbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: Mechanisms and implications. Biochem. Cell Biol. 75:315-325.
Y. Liu, D. El-Ashry, D. Chen, I. F. Y. Ding, and F. G. Kern (1995). MCF-7 breast cancer cells overexpressing transfected c-erbB2 have an in vitro growth advantage in estrogen-depleted conditions and a reduced estrogen-dependence and tamoxifen sensitivity in vivo. Breast Cancer Res. Treat. 34:97-117.
H. Kurokawa, A. E. G. Lenferink, J. F. Simpson, P. I. Pisacane, M. X. Sliwkowski, J. T. Forbes, and C. L. Arteaga (2000). Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER-2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 60:5887-5894.
D. Yu and M.-C. Hung (2000). Overexpression of erbB2 in cancer and erbB2-targeting strategies. Oncogene 19:6115-6121.
C. I. Sartor (2000). Biological modifiers as potential radiosensitizers: Targeting the epidermal growth factor receptor family. Semin. Oncol. 27:15-20.
G. S. Rao, S. Murray, and S. P. Ethier (2000). Radiosensitization of human breast cancer cells by a novel erbB family receptor tyrosine kinase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 48:1519-1528.
M. De Bortoli and C. Dati (1997). Hormonal regulation of type 1 receptor tyrosine kinase expression in the mammary gland. J. Mammary Gland Biol. Neoplasia 2:175-185.
R. J. Pietras, J. Arboleda, D. M. Reese, N. Wongvipat, M. Pegram, L. Ramos, C. M. Gorman, M. G. Parker, M. X. Sliwkowski, and D. J. Slamon (1995). HER-2 tyrosine kinase pathway targets estrogen receptors and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446.
M. E. Balana, R. Lupu, L. Labriola, E. H. Charreau, and P. V. Elizalde (1999). Interactions between progestins and heregulin (HRG) signalling pathways:HRGacts as a mediator of progestins proliferative effects in mouse mammary adenocarcinoma. Oncogene 18:6370-6379.
S. A. Eccles, W. J. Court, G. A. Box, C. J. Dean, R. G. Melton, and C. J. Springer (1999). Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res. 54:5171-5177.
S. A. Eccles (1998). c-erbB-2 as a target for immunotherapy. Exp. Opinion Invest. Drugs. 7:1879-1896.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eccles, S.A. The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis. J Mammary Gland Biol Neoplasia 6, 393–406 (2001). https://doi.org/10.1023/A:1014730829872
Issue Date:
DOI: https://doi.org/10.1023/A:1014730829872